Core patent protection for Matrix-M Adjuvant extends through 2044 and beyond. Predicting Novavax will be ACQUIRED due to the $BILLIONS in revenues Matrix-M will bring to the buyer over the next few decades with adjuvanted Cancer, Infectious Disease, C.Diff., and Respiratory Vaccines. $NVAX #Biotech $IBB $XBI https://t.co/JollrXJ5vH

Next week’s Novavax Q3’26 earnings call would be the perfect opportunity to announce the oncology partnership. A lot of great things happening at $NVAX. PS- Current Short Interest is 32.38% with 7 days to cover.😁 #Biotech https://t.co/VND7b4ACcF https://t.co/YTLbIH8mEw

🚨Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe. October 29, 2026 $NVAX $SNY $IBB $XBI #Biotech https://t.co/JdqOYEfNLz https://t.co/CCdYWvNyCN

Novavax’s Nuvaxovid is now the sole COVID-19 vaccine available in Sweden. Expect more countries to follow Sweden’s lead. $NVAX #Biotech $IBB $XBI $SNY $PFE $MRNA $BNTX

Big News!!! Sweden opts for Novavax’s Nuvaxovid, says goodbye to mRNA-based COVID-19 vaccines. $NVAX #Biotech $IBB $PFE $MRNA $SNY https://t.co/alnRWqqI3G https://t.co/qDlWkiIDp9

StockNewsRoomCOM is a fraud. Shah still holds 10-12M shares of $NVAX. Shah never held 32M shares. PS: Novavax is 86.44% Inst’l owned. See the following link for proof: https://t.co/v58JNJmmm2 #Biotech $IBB $XBI https://t.co/bxO5FkLwnt

$NVAX big presence at World Vaccine Congress Europe 2026 19 - 21 October, Amsterdam •Day 1: The Technology Revolution: Agility for the Wave of Next Generation Vaccines •Day 2: The Potential of Novavax’s Technology Platform, including Matrix-M® adjuvant #Biotech $IBB https://t.co/ZPQKZlJ1Fd

🦠Novavax $NVAX Matrix-M Adjuvant Utility in Pandemic Diseases: • Rapid Response Potential: Serves as a critical asset for future Novavax pandemic preparedness frameworks targeting novel influenza strains, Ebola, & other high-consequence pathogens. #Biotech $IBB https://t.co/GfHIYS49Em

$INTC - $SOUN PARTNERSHIP. #AI

🚨 $SOUN $INTC #AI